InteKrin Therapeutics Announces Initiation of Phase 2b Study in ... - PR Newswire (press release)
This placebo controlled, double-blind, Phase 2b study includes multiple doses of orally administered INT131 once daily, and Actos(R) (pioglitazone) as an ...